# Once Versus Twice Bisoprolol Dosage Regimen in Prevention of Atrial Fibrillation Post Coronary Artery Bypass Graft Surgery

Study · id `cardio:ct-nct05730413` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05730413](<https://clinicaltrials.gov/study/NCT05730413>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05730413

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 122 participants.

## Technical summary

Registry record NCT05730413. Randomized; no masking; primary purpose prevention. Start 2021-08-25 (actual); primary completion 2023-09 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose prevention
- Phase: Phase 4
- Enrolled: 122 participants (planned count; ClinicalTrials.gov record NCT05730413, source copy `cardio:ctgov-nct05730413-2023-07-28`, retrieved 2026-10-26)
- Started: 2021-08-25 (actual) (ClinicalTrials.gov record NCT05730413, source copy `cardio:ctgov-nct05730413-2023-07-28`, retrieved 2026-10-26)
- Primary completion: 2023-09 (anticipated) (ClinicalTrials.gov record NCT05730413, source copy `cardio:ctgov-nct05730413-2023-07-28`, retrieved 2026-10-26)
- Completion: 2023-09 (anticipated) (ClinicalTrials.gov record NCT05730413, source copy `cardio:ctgov-nct05730413-2023-07-28`, retrieved 2026-10-26)
- Countries: Egypt (ClinicalTrials.gov record NCT05730413, source copy `cardio:ctgov-nct05730413-2023-07-28`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05730413-2023-07-28`, retrieved 2026-10-26)

## The registry's words

- Brief title: Once Versus Twice Bisoprolol Dosage Regimen in Prevention of Atrial Fibrillation Post Coronary Artery Bypass Graft Surgery
- Condition: Coronary Artery Bypass Grafting
- Condition: Postoperative Atrial Fibrillation
- Condition: Coronary Artery Disease
- Intervention (Drug): Bisoprolol
- Intervention (Drug): Bisoprolol
- Lead sponsor: Cairo University
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry intervention name matches this record: Bisoprolol (`cardio:bisoprolol`)
- Registry intervention is a member of this class by a sourced record link: Beta-blockers (drug class) (`cardio:beta-blockers`)
- Registry lists this organization as the lead sponsor: Cairo University (`cardio:org-cairo-university`)

## Provenance

Content hash: 913aaa2100da9fa24eab348248be6a9ae71dfec4ad7f05fba2a69ea5b6b64d03
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
